title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug,20241211T150200,https://www.zacks.com/stock/news/2382224/qure-soars-on-fda-alignment-for-speedy-approval-of-huntingtons-drug,QURE,0.211191,Somewhat-Bullish,0.274281
"Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More",20241211T145500,https://www.zacks.com/stock/news/2382213/biotech-stock-roundup-bioa-down-on-study-update-qure-crdf-gain-on-study-data-more,QURE,0.12003,Somewhat-Bullish,0.257279
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease,20241210T120500,https://www.globenewswire.com/news-release/2024/12/10/2994386/0/en/uniQure-Announces-Alignment-with-FDA-on-Key-Elements-of-Accelerated-Approval-Pathway-for-AMT-130-in-Huntington-s-Disease.html,QURE,0.048621,Neutral,0.120782
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy,20241121T120500,https://www.globenewswire.com/news-release/2024/11/21/2985098/0/en/uniQure-Announces-Dosing-of-First-Patient-in-GenTLE-Phase-I-IIa-Clinical-Trial-of-AMT-260-for-the-Treatment-of-Refractory-Mesial-Temporal-Lobe-Epilepsy.html,QURE,0.085936,Neutral,0.091577
uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress,20241105T120500,https://www.globenewswire.com/news-release/2024/11/05/2974805/0/en/uniQure-Announces-Third-Quarter-2024-Financial-Results-and-Highlights-Recent-Company-Progress.html,QURE,0.032425,Neutral,0.043202
uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS,20241015T110500,https://www.globenewswire.com/news-release/2024/10/15/2963063/0/en/uniQure-Announces-Dosing-of-First-Patient-in-Phase-I-II-Clinical-Trial-of-AMT-162-for-the-Treatment-SOD1-ALS.html,QURE,0.076358,Neutral,0.092449
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease,20240923T110500,https://www.globenewswire.com/news-release/2024/09/23/2951251/0/en/uniQure-Announces-Orphan-Drug-Designation-Granted-to-AMT-191-for-the-Treatment-of-Fabry-Disease.html,QURE,0.078226,Neutral,0.028674
"Gene Therapy Market Set for 19% CAGR Surge, Reaching USD 38.34 Billion by 2031 | SkyQuest Technology",20240912T133000,https://www.benzinga.com/pressreleases/24/09/g40833623/gene-therapy-market-set-for-19-cagr-surge-reaching-usd-38-34-billion-by-2031-skyquest-technology,QURE,0.039878,Neutral,0.026899
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease,20240815T110500,https://www.globenewswire.com/news-release/2024/08/15/2930804/0/en/uniQure-Announces-Dosing-of-First-Patient-in-Phase-I-IIa-Clinical-Trial-of-AMT-191-for-the-Treatment-of-Fabry-Disease.html,QURE,0.072435,Neutral,0.082865
uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update,20240801T110500,https://www.globenewswire.com/news-release/2024/08/01/2922648/0/en/uniQure-Announces-Second-Quarter-2024-Financial-Results-and-Provides-Company-Update.html,QURE,0.033144,Neutral,0.04332
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen,20240723T110500,https://www.globenewswire.com/news-release/2024/07/23/2917097/0/en/uniQure-Announces-Closing-of-Sale-of-Manufacturing-Facility-to-Genezen.html,QURE,0.069697,Neutral,-0.023246
"Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure",20240711T131200,https://www.zacks.com/stock/news/2300042/biotech-stock-roundup-kymr-idya-qure-soar-on-study-data-hlvx-tanks-on-study-failure,QURE,0.078482,Neutral,0.125886
UniQure Soars on New Huntington's Disease Study Data,20240710T205623,https://markets.businessinsider.com/news/stocks/uniqure-soars-on-new-huntington-s-disease-study-data-1033544723,QURE,0.081276,Neutral,0.054774
uniQure  ( QURE )  Soars on New Huntington's Disease Study Data,20240710T130100,https://www.zacks.com/stock/news/2299274/uniqure-qure-soars-on-new-huntingtons-disease-study-data,QURE,0.117486,Neutral,0.05768
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington's Disease,20240709T110500,https://www.globenewswire.com/news-release/2024/07/09/2910220/0/en/uniQure-Announces-Positive-Interim-Data-Update-Demonstrating-Slowing-of-Disease-Progression-in-Phase-I-II-Trials-of-AMT-130-for-Huntington-s-Disease.html,QURE,0.03387,Neutral,-0.008544
uniQure Announces Sale of Commercial Manufacturing Facility to Genezen,20240701T110500,https://www.globenewswire.com/news-release/2024/07/01/2906599/0/en/uniQure-Announces-Sale-of-Commercial-Manufacturing-Facility-to-Genezen.html,QURE,0.064104,Neutral,0.021135
uniQure Receives FDA Regenerative Medicine Advanced Therapy  ( RMAT )  Designation for Investigational Gene Therapy AMT-130 in Huntington's Disease,20240603T110500,https://www.globenewswire.com/news-release/2024/06/03/2892124/0/en/uniQure-Receives-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-for-Investigational-Gene-Therapy-AMT-130-in-Huntington-s-Disease.html,QURE,0.054794,Neutral,0.055999
uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress,20240507T110500,https://www.globenewswire.com/news-release/2024/05/07/2876578/0/en/uniQure-Announces-First-Quarter-2024-Financial-Results-and-Highlights-Recent-Company-Progress.html,QURE,0.044885,Neutral,0.044682
"uniQure  ( NASDAQ:QURE )  Upgraded to ""Sell"" at StockNews.com",20240303T074844,https://www.defenseworld.net/2024/03/03/uniqure-nasdaqqure-upgraded-to-sell-at-stocknews-com.html,QURE,0.098862,Neutral,0.019384
uniQure Announces 2023 Financial Results and Highlights Recent Company Progress,20240228T120500,https://www.globenewswire.com/news-release/2024/02/28/2836825/0/en/uniQure-Announces-2023-Financial-Results-and-Highlights-Recent-Company-Progress.html,QURE,0.043264,Neutral,0.042552
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington's Disease,20231219T120500,https://www.globenewswire.com/news-release/2023/12/19/2798425/0/en/uniQure-Announces-Update-on-Phase-I-II-Clinical-Trials-of-AMT-130-Gene-Therapy-for-the-Treatment-of-Huntington-s-Disease.html,QURE,0.03072,Neutral,-0.009359
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ,20231208T120500,https://www.globenewswire.com/news-release/2023/12/08/2793129/0/en/uniQure-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,QURE,0.24289,Somewhat-Bullish,0.207303
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease,20231129T120500,https://www.globenewswire.com/news-release/2023/11/29/2787620/0/en/uniQure-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-AMT-191-Gene-Therapy-for-Fabry-Disease.html,QURE,0.097259,Neutral,0.076751
uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress,20231107T120500,https://www.globenewswire.com/news-release/2023/11/07/2774943/0/en/uniQure-Announces-Third-Quarter-2023-Financial-Results-and-Highlights-Recent-Company-Progress.html,QURE,0.043499,Neutral,0.044577
CSL and uniQure Win 2023 Prix Galien USA Award,20231027T140000,https://www.prnewswire.com/news-releases/csl-and-uniqure-win-2023-prix-galien-usa-award-301970222.html,QURE,0.063933,Neutral,0.124601
uniQure Announces Major Presence at the European Society of Gene and Cell Therapy  ( ESGCT )  Annual Meeting,20231024T110500,https://www.globenewswire.com/news-release/2023/10/24/2765472/0/en/uniQure-Announces-Major-Presence-at-the-European-Society-of-Gene-and-Cell-Therapy-ESGCT-Annual-Meeting.html,QURE,0.100518,Neutral,-0.010731
"Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors",20231016T115000,https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-appoints-life-science-industry-leaders-jeremy-bender-teresa-bitetti-and-david-meek-to-its-board-of-directors-301957344.html,QURE,0.044386,Neutral,-0.02047
"Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors",20231016T115000,https://www.newswire.ca/news-releases/fusion-pharmaceuticals-appoints-life-science-industry-leaders-jeremy-bender-teresa-bitetti-and-david-meek-to-its-board-of-directors-816998848.html,QURE,0.044386,Neutral,-0.02047
"Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback",20231012T122400,https://www.zacks.com/stock/news/2164807/biotech-stock-roundup-bmy-grabs-mrtx-akro-down-on-study-data-alny-faces-setback,QURE,0.067441,Neutral,-0.02003
"uniQure  ( QURE )  Up on Restructuring Plans, Workforce Reduction",20231006T153100,https://www.zacks.com/stock/news/2161746/uniqure-qure-up-on-restructuring-plans-workforce-reduction,QURE,0.302243,Neutral,-0.090642
uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs,20231005T110500,https://www.globenewswire.com/news-release/2023/10/05/2755260/0/en/uniQure-Announces-Strategic-Reorganization-to-Reduce-Operating-Expenses-and-Support-Advancement-of-Multiple-Clinical-Stage-Programs.html,QURE,0.051496,Neutral,0.08896
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ,20231002T110500,https://www.globenewswire.com/news-release/2023/10/02/2752634/0/en/uniQure-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,QURE,0.241684,Somewhat-Bullish,0.206503
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy,20230905T110500,https://www.globenewswire.com/news-release/2023/09/05/2737179/0/en/uniQure-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-AMT-260-Gene-Therapy-for-Refractory-Mesial-Temporal-Lobe-Epilepsy.html,QURE,0.098659,Neutral,-0.043854
"Blackstone and Airbnb Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400 and S&P SmallCap 600",20230901T225100,https://markets.businessinsider.com/news/stocks/blackstone-and-airbnb-set-to-join-s-p-500-others-to-join-s-p-100-s-p-midcap-400-and-s-p-smallcap-600-1032600818,QURE,0.057215,Neutral,0.111956
StockNews.com Downgrades uniQure  ( NASDAQ:QURE )  to Sell,20230808T091044,https://www.defenseworld.net/2023/08/08/stocknews-com-downgrades-uniqure-nasdaqqure-to-sell.html,QURE,0.084127,Neutral,0.037204
uniQure  ( NASDAQ:QURE )  Stock Rating Upgraded by StockNews.com,20230802T063242,https://www.defenseworld.net/2023/08/02/uniqure-nasdaqqure-stock-rating-upgraded-by-stocknews-com.html,QURE,0.146025,Neutral,0.128387
uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress,20230801T110500,https://www.globenewswire.com/news-release/2023/08/01/2715661/0/en/uniQure-Announces-Second-Quarter-2023-Financial-Results-and-Highlights-Recent-Company-Progress.html,QURE,0.032602,Neutral,0.043231
StockNews.com Lowers uniQure  ( NASDAQ:QURE )  to Sell,20230720T052248,https://www.defenseworld.net/2023/07/20/stocknews-com-lowers-uniqure-nasdaqqure-to-sell.html,QURE,0.049019,Neutral,0.018992
uniQure  ( NASDAQ:QURE )  Stock Rating Lowered by StockNews.com,20230709T054241,https://www.defenseworld.net/2023/07/09/uniqure-nasdaqqure-stock-rating-lowered-by-stocknews-com.html,QURE,0.147818,Neutral,0.096941
uniQure  ( NASDAQ:QURE )  Downgraded to Sell at StockNews.com,20230708T081641,https://www.defenseworld.net/2023/07/08/uniqure-nasdaqqure-downgraded-to-sell-at-stocknews-com.html,QURE,0.089462,Neutral,0.02309
uniQure Announces Leadership Addition to Support Advancement of Clinical Programs,20230626T111100,https://www.globenewswire.com/news-release/2023/06/26/2694317/0/en/uniQure-Announces-Leadership-Addition-to-Support-Advancement-of-Clinical-Programs.html,QURE,0.072987,Neutral,0.07789
uniQure  ( QURE )  Falls on Mixed Huntington's Disease Study Results,20230622T141700,https://www.zacks.com/stock/news/2111826/uniqure-qure-falls-on-mixed-huntingtons-disease-study-results,QURE,0.239541,Neutral,-0.067882
uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington's Disease,20230621T110500,https://www.globenewswire.com/news-release/2023/06/21/2691872/0/en/uniQure-Announces-Update-on-U-S-Phase-I-II-Clinical-Trial-of-AMT-130-Gene-Therapy-for-the-Treatment-of-Huntington-s-Disease.html,QURE,0.032425,Neutral,0.031437
uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy,20230620T110500,https://www.globenewswire.com/news-release/2023/06/20/2690928/0/en/uniQure-announces-achievement-of-100-million-milestone-related-to-hemophilia-B-gene-therapy.html,QURE,0.056143,Neutral,-0.036051
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ,20230616T110500,https://www.globenewswire.com/news-release/2023/06/16/2689651/0/en/uniQure-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,QURE,0.178459,Somewhat-Bullish,0.16282
uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million,20230515T110500,https://www.globenewswire.com/news-release/2023/05/15/2668613/0/en/uniQure-Announces-Sale-of-Royalty-Interest-in-HEMGENIX-for-Up-To-400-Million.html,QURE,0.057559,Neutral,-0.005003
uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress,20230509T110500,https://www.globenewswire.com/news-release/2023/05/09/2664265/0/en/uniQure-Announces-First-Quarter-2023-Financial-Results-and-Highlights-Recent-Company-Progress.html,QURE,0.042159,Neutral,0.042457
uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy  ( ASGCT )  Annual Meeting,20230502T204000,https://www.globenewswire.com/news-release/2023/05/02/2659829/0/en/uniQure-Announces-Major-Presence-at-Upcoming-American-Society-of-Gene-and-Cell-Therapy-ASGCT-Annual-Meeting.html,QURE,0.093289,Neutral,-0.010515
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ,20230502T110500,https://www.globenewswire.com/news-release/2023/05/02/2658987/0/en/uniQure-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,QURE,0.295867,Somewhat-Bullish,0.331448
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ,20230313T110500,https://www.globenewswire.com/news-release/2023/03/13/2625574/0/en/uniQure-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,QURE,0.252987,Somewhat-Bullish,0.289352
"Hefty Listing Price Of New Drugs For Cancer, Rare Diseases Put Pressure On Annual Hike For Older Drugs - bluebird bio  ( NASDAQ:BLUE ) , Amgen  ( NASDAQ:AMGN ) ",20230310T181042,https://www.benzinga.com/general/biotech/23/03/31300483/hefty-listing-price-of-new-drugs-for-cancer-rare-diseases-put-pressure-on-annual-hike-for-older-d,QURE,0.210274,Neutral,0.0
uniQure to Participate in Multiple Upcoming Industry Conferences in March,20230302T120500,https://www.globenewswire.com/news-release/2023/03/02/2619154/0/en/uniQure-to-Participate-in-Multiple-Upcoming-Industry-Conferences-in-March.html,QURE,0.139669,Neutral,0.018452
uniQure Announces 2022 Financial Results and Highlights Recent Company Progress,20230227T120500,https://www.globenewswire.com/news-release/2023/02/27/2615948/0/en/uniQure-Announces-2022-Financial-Results-and-Highlights-Recent-Company-Progress.html,QURE,0.037358,Neutral,0.045929
"uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX®  ( etranacogene dezaparvovec-drlb ) ",20230223T130500,https://www.globenewswire.com/news-release/2023/02/23/2614293/0/en/uniQure-Announces-HOPE-B-Clinical-Trial-Data-Published-in-the-New-England-Journal-of-Medicine-Demonstrating-Durability-and-Other-Benefits-of-HEMGENIX-etranacogene-dezaparvovec-drlb.html,QURE,0.04028,Neutral,-0.040584
uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B,20230221T120500,https://www.globenewswire.com/news-release/2023/02/21/2611969/0/en/uniQure-announces-the-European-Commission-approval-of-the-first-gene-therapy-for-adults-with-hemophilia-B.html,QURE,0.040587,Neutral,-0.110937
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ,20221220T120500,https://www.globenewswire.com/news-release/2022/12/20/2576954/0/en/uniQure-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,QURE,0.215894,Somewhat-Bullish,0.223646
EU regulator backs gene therapy to treat rare bleeding disorder,20221216T121800,https://www.reuters.com/business/healthcare-pharmaceuticals/eu-regulator-backs-gene-therapy-treat-rare-bleeding-disorder-2022-12-16/,QURE,0.380012,Neutral,0.146509
uniQure announces positive CHMP opinion for etranacogene dezaparvovec - gene therapy for adults with hemophilia B,20221216T121500,https://www.globenewswire.com/news-release/2022/12/16/2575374/0/en/uniQure-announces-positive-CHMP-opinion-for-etranacogene-dezaparvovec-gene-therapy-for-adults-with-hemophilia-B.html,QURE,0.055751,Neutral,0.033006
uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy  ( rTLE )  at Virtual Research & Development Event,20221129T160000,https://www.globenewswire.com/news-release/2022/11/29/2564284/0/en/uniQure-Highlights-Therapeutic-Potential-of-AMT-260-in-Refractory-Temporal-Lobe-Epilepsy-rTLE-at-Virtual-Research-Development-Event.html,QURE,0.067347,Neutral,0.108426
uniQure announces FDA approval of first gene therapy for adults with hemophilia B,20221122T214000,https://www.globenewswire.com/news-release/2022/11/22/2561267/0/en/uniQure-announces-FDA-approval-of-first-gene-therapy-for-adults-with-hemophilia-B.html,QURE,0.033375,Neutral,-0.002888
"uniQure to Host Virtual Research & Development Event on Tuesday, November 29, 2022",20221117T120500,https://www.globenewswire.com/news-release/2022/11/17/2558039/0/en/uniQure-to-Host-Virtual-Research-Development-Event-on-Tuesday-November-29-2022.html,QURE,0.282234,Neutral,-0.022928
uniQure Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress,20221102T110500,https://www.globenewswire.com/news-release/2022/11/02/2546342/0/en/uniQure-Announces-Third-Quarter-2022-Financial-Results-and-Highlights-Recent-Company-Progress.html,QURE,0.042496,Neutral,0.044492
uniQure Announces Multiple Presentations at the Upcoming Annual Meeting of The European Society of Gene and Cell Therapy  ( ESGCT ) ,20221011T110500,https://www.globenewswire.com/news-release/2022/10/11/2531670/0/en/uniQure-Announces-Multiple-Presentations-at-the-Upcoming-Annual-Meeting-of-The-European-Society-of-Gene-and-Cell-Therapy-ESGCT.html,QURE,0.150122,Neutral,-0.012875
uniQure to Participate in Upcoming Industry Conferences in October,20221003T110500,https://www.globenewswire.com/news-release/2022/10/03/2526678/0/en/uniQure-to-Participate-in-Upcoming-Industry-Conferences-in-October.html,QURE,0.2872,Neutral,-0.00622
uniQure to Participate in Upcoming Industry Conferences in September,20220906T110500,https://www.globenewswire.com/news-release/2022/09/06/2510230/0/en/uniQure-to-Participate-in-Upcoming-Industry-Conferences-in-September.html,QURE,0.166743,Neutral,0.013605
uniQure  ( NASDAQ:QURE )  Downgraded by StockNews.com to Sell,20220814T095455,https://reporter.am/2022/08/14/uniqure-nasdaqqure-downgraded-by-stocknews-com-to-sell.html,QURE,0.190793,Neutral,0.086539
uniQure  ( NASDAQ:QURE )  Downgraded by StockNews.com,20220812T060442,https://www.defenseworld.net/2022/08/12/uniqure-nasdaqqure-downgraded-by-stocknews-com.html,QURE,0.191549,Neutral,0.141492
uniQure  ( NASDAQ:QURE )  Rating Lowered to Sell at StockNews.com,20220812T060442,https://www.etfdailynews.com/2022/08/12/uniqure-nasdaqqure-rating-lowered-to-sell-at-stocknews-com/,QURE,0.19117,Neutral,0.0727
Why uniQure Stock Is Crashing Today,20220808T155350,https://www.fool.com/investing/2022/08/08/why-uniqure-stock-is-crashing-today/,QURE,0.288893,Bearish,-0.391619
uniQure Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress,20220808T110500,https://www.globenewswire.com/news-release/2022/08/08/2493736/0/en/uniQure-Announces-Second-Quarter-2022-Financial-Results-and-Highlights-Recent-Company-Progress.html,QURE,0.036228,Neutral,0.043781
"Uniqure Stock Sees Healthy Price Gain, Ranks Among Top 8%",20220711T223000,https://www.investors.com/news/technology/stock-upgrades-uniqure-n-v-shows-rising-relative-strength-3/,QURE,0.172097,Somewhat-Bullish,0.207572
uniQure  ( QURE )  Up on Safety Data From Huntington's Disease Study,20220624T143000,https://www.zacks.com/stock/news/1943610/uniqure-qure-up-on-safety-data-from-huntingtons-disease-study,QURE,0.140896,Neutral,0.033266
Why UniQure Shares Are Trading Higher Today,20220623T180522,https://www.benzinga.com/general/biotech/22/06/27830566/uniqure-shares-are-up-after-low-dose-cohort-data-from-huntingtons-gene-therapy-trial,QURE,0.524949,Neutral,0.021764
uniQure Announces Update on Low-Dose Cohort in Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington's Disease,20220623T110500,https://www.globenewswire.com/news-release/2022/06/23/2467860/0/en/uniQure-Announces-Update-on-Low-Dose-Cohort-in-Phase-I-II-Clinical-Trial-of-AMT-130-Gene-Therapy-for-the-Treatment-of-Huntington-s-Disease.html,QURE,0.041527,Neutral,0.019795
CORRECTION -- uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ,20220622T203400,https://www.globenewswire.com/news-release/2022/06/22/2467524/0/en/CORRECTION-uniQure-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,QURE,0.468029,Neutral,0.009244
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ,20220622T110500,https://www.globenewswire.com/news-release/2022/06/22/2466978/0/en/uniQure-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,QURE,0.266391,Neutral,0.007599
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ,20220622T110500,https://www.benzinga.com/pressreleases/22/06/g27808639/uniqure-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4,QURE,0.252071,Neutral,0.003529
uniQure  ( NASDAQ:QURE )  Stock Rating Upgraded by StockNews.com,20220609T021842,https://www.defenseworld.net/2022/06/09/uniqure-nasdaqqure-stock-rating-upgraded-by-stocknews-com.html,QURE,0.244354,Neutral,0.010525
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ,20220511T110500,https://www.globenewswire.com/news-release/2022/05/11/2440669/0/en/uniQure-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,QURE,0.269033,Neutral,0.00576
uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635 ( c )  ( 4 ) ,20220511T110500,https://www.benzinga.com/pressreleases/22/05/g27131298/uniqure-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4,QURE,0.256179,Neutral,0.004776
uniQure  ( NASDAQ:QURE )  Lowered to Sell at StockNews.com,20220510T085845,https://www.defenseworld.net/2022/05/10/uniqure-nasdaqqure-lowered-to-sell-at-stocknews-com.html,QURE,0.168687,Neutral,0.016025
uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy  ( ASGCT )  Annual Meeting,20220502T204500,https://www.globenewswire.com/news-release/2022/05/02/2434019/0/en/uniQure-Announces-Multiple-Presentations-at-Upcoming-American-Society-of-Gene-and-Cell-Therapy-ASGCT-Annual-Meeting.html,QURE,0.160099,Neutral,0.011115
uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy  ( ASGCT )  Annual Meeting,20220502T204500,https://www.benzinga.com/pressreleases/22/05/g26948470/uniqure-announces-multiple-presentations-at-upcoming-american-society-of-gene-and-cell-therapy-asg,QURE,0.151682,Neutral,0.01345
uniQure Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress,20220502T110500,https://www.globenewswire.com/news-release/2022/05/02/2433340/0/en/uniQure-Announces-First-Quarter-2022-Financial-Results-and-Highlights-Recent-Company-Progress.html,QURE,0.033585,Neutral,0.030096
uniQure Announces Completion of Patient Enrollment in the First Two Cohorts of its Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington's Disease,20220321T110500,https://www.globenewswire.com/news-release/2022/03/21/2406555/0/en/uniQure-Announces-Completion-of-Patient-Enrollment-in-the-First-Two-Cohorts-of-its-Phase-I-II-Clinical-Trial-of-AMT-130-for-the-Treatment-of-Huntington-s-Disease.html,QURE,0.114682,Neutral,0.010346
